Schroder Investment Management Group Increases Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Schroder Investment Management Group raised its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 548.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 533,111 shares of the company's stock after buying an additional 450,924 shares during the quarter. Schroder Investment Management Group owned about 0.93% of Olema Pharmaceuticals worth $2,991,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its holdings in shares of Olema Pharmaceuticals by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 332,950 shares of the company's stock worth $1,941,000 after purchasing an additional 2,189 shares in the last quarter. EP Wealth Advisors LLC boosted its holdings in Olema Pharmaceuticals by 5.2% during the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company's stock valued at $581,000 after acquiring an additional 2,407 shares during the period. SG Americas Securities LLC boosted its holdings in Olema Pharmaceuticals by 33.8% during the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company's stock valued at $102,000 after acquiring an additional 4,419 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Olema Pharmaceuticals during the 4th quarter valued at about $30,000. Finally, Dana Investment Advisors Inc. boosted its holdings in Olema Pharmaceuticals by 7.3% during the 4th quarter. Dana Investment Advisors Inc. now owns 92,039 shares of the company's stock valued at $537,000 after acquiring an additional 6,232 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OLMA has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th. JPMorgan Chase & Co. dropped their target price on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Friday, March 28th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.

Olema Pharmaceuticals Trading Up 1.7 %

NASDAQ OLMA traded up $0.06 on Thursday, hitting $3.21. The company's stock had a trading volume of 278,903 shares, compared to its average volume of 850,280. Olema Pharmaceuticals, Inc. has a 52-week low of $2.86 and a 52-week high of $16.62. The company's 50-day simple moving average is $4.45 and its 200 day simple moving average is $7.43. The firm has a market cap of $219.01 million, a P/E ratio of -1.46 and a beta of 2.10.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. On average, research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.